{"id":53265,"date":"2026-01-08T00:38:24","date_gmt":"2026-01-07T16:38:24","guid":{"rendered":"https:\/\/flcube.com\/?p=53265"},"modified":"2026-01-08T00:38:25","modified_gmt":"2026-01-07T16:38:25","slug":"amgen-acquires-dark-blue-therapeutics-for-840-million-to-expand-aml-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53265","title":{"rendered":"Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio"},"content":{"rendered":"\n<p><strong>Amgen Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/AMGN:NASDAQ\">NASDAQ: AMGN<\/a>)<\/strong> announced the acquisition of <strong>Dark Blue Therapeutics Ltd.<\/strong>, a privately held UK\u2011based biotech advancing <strong>first\u2011in\u2011class small\u2011molecule protein degraders<\/strong> for oncology, in a transaction valued at up to <strong>USD\u202f840\u202fmillion<\/strong>. The deal adds an investigational dual\u2011target degrader for <strong>acute myeloid leukemia (AML)<\/strong> to Amgen\u2019s early\u2011stage oncology pipeline, with promising preclinical data demonstrating anti\u2011cancer activity and potential to overcome treatment resistance.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Amgen Inc. (NASDAQ: AMGN)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Dark Blue Therapeutics Ltd. (UK, privately held)<\/td><\/tr><tr><td><strong>Deal Value<\/strong><\/td><td>Up to <strong>USD\u202f840\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Investigational dual\u2011target protein degrader (MLLT1\/3)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Acute myeloid leukemia (AML)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>First\u2011in\u2011class small\u2011molecule targeted protein degrader<\/td><\/tr><tr><td><strong>Use of Asset<\/strong><\/td><td>Single\u2011agent and combination therapy to overcome resistance<\/td><\/tr><tr><td><strong>Integration<\/strong><\/td><td>Dark Blue to be integrated into Amgen\u2019s research organization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-dual-target-protein-degrader\">Technology Profile: Dual\u2011Target Protein Degrader<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: The investigational molecule is a <strong>small\u2011molecule protein degrader<\/strong> that <strong>simultaneously targets and degrades MLLT1 and MLLT3 proteins<\/strong>, which drive specific AML subtypes.<\/p>\n\n\n\n<p><strong>Preclinical Data<\/strong>: Demonstrated <strong>promising anti\u2011cancer activity<\/strong> in AML models, with <strong>mechanistic differentiation<\/strong> from existing therapies (chemotherapy, FLT3 inhibitors, IDH inhibitors).<\/p>\n\n\n\n<p><strong>Strategic Advantage<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Overcomes Treatment Resistance<\/strong>: Addresses resistance mechanisms to current AML therapies<\/li>\n\n\n\n<li><strong>Combination Potential<\/strong>: Synergizes with venetoclax\u2011based regimens and hypomethylating agents<\/li>\n\n\n\n<li><strong>Durability<\/strong>: Degradation\u2011based approach may provide <strong>longer\u2011lasting remissions<\/strong> vs. inhibition alone<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-acute-myeloid-leukemia\">Market Opportunity: Acute Myeloid Leukemia<\/h2>\n\n\n\n<p><strong>AML Prevalence<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Incidence<\/strong>: <strong>200,000+<\/strong> new cases annually<\/li>\n\n\n\n<li><strong>U.S. Market<\/strong>: <strong>21,000<\/strong> new cases, <strong>$2.8\u202fbillion<\/strong> market (2025)<\/li>\n\n\n\n<li><strong>Treatment Landscape<\/strong>: Dominated by <strong>intensive chemotherapy<\/strong>, <strong>venetoclax + azacitidine<\/strong>, and <strong>targeted agents<\/strong> (FLT3, IDH inhibitors)<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: <strong>30\u201140%<\/strong> of patients relapse or are refractory to frontline therapy; <strong>no approved therapies<\/strong> targeting MLLT1\/3<\/li>\n<\/ul>\n\n\n\n<p><strong>Revenue Potential<\/strong>: Peak sales for the dual\u2011target degrader estimated at <strong>$500\u2011800\u202fmillion<\/strong> globally by 2032, assuming <strong>10\u201115%<\/strong> penetration of relapsed\/refractory AML market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Asset<\/th><th>Mechanism<\/th><th>Stage<\/th><th>AML Focus<\/th><\/tr><\/thead><tbody><tr><td><strong>Amgen + Dark Blue<\/strong><\/td><td><strong>MLLT1\/3 Degrader<\/strong><\/td><td>Protein degradation<\/td><td><strong>Preclinical<\/strong><\/td><td><strong>Novel target<\/strong><\/td><\/tr><tr><td><strong>Syndax + Incyte<\/strong><\/td><td>Revumenib<\/td><td>Menin inhibitor<\/td><td>Phase\u202fIII<\/td><td>MLL\u2011r AML<\/td><\/tr><tr><td><strong>Foghorn Therapeutics<\/strong><\/td><td>FHD-286<\/td><td>BRG1\/BRM inhibitor<\/td><td>Phase\u202fI<\/td><td>MLL\u2011r AML<\/td><\/tr><tr><td><strong>AbbVie + Genentech<\/strong><\/td><td>Venclexta<\/td><td>BCL\u20112 inhibitor<\/td><td>Marketed<\/td><td>1L\/relapsed<\/td><\/tr><tr><td><strong>BMS<\/strong><\/td><td>Onureg<\/td><td>Maintenance therapy<\/td><td>Marketed<\/td><td>Maintenance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: The <strong>MLLT1\/3 degrader<\/strong> is the <strong>first to target this specific oncogenic driver<\/strong>, offering <strong>potential for combination<\/strong> with existing agents in <strong>high\u2011risk AML subtypes<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-for-amgen\">Strategic Rationale for Amgen<\/h2>\n\n\n\n<p><strong>Pipeline Gap Fill<\/strong>: Amgen\u2019s oncology portfolio is <strong>strong in solid tumors<\/strong> (Lumakras, Tarceva) but <strong>limited in hematologic malignancies<\/strong>; this acquisition <strong>builds an AML franchise<\/strong>.<\/p>\n\n\n\n<p><strong>Technology Acquisition<\/strong>: Gains <strong>proprietary protein degrader platform<\/strong>, enabling <strong>expansion into other oncology targets<\/strong> (e.g., transcription factors, epigenetic regulators).<\/p>\n\n\n\n<p><strong>Cost Synergies<\/strong>: <strong>Integrates Dark Blue\u2019s 25\u2011person UK R&amp;D team<\/strong> into Amgen\u2019s <strong>Cambridge (U.S.) and Cambridge (UK) research hubs<\/strong>, leveraging existing infrastructure.<\/p>\n\n\n\n<p><strong>Financial Accretion<\/strong>: Deal expected to be <strong>accretive by 2029<\/strong> upon Phase\u202fIII success and launch.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-financial-terms\">Deal Structure &amp; Financial Terms<\/h2>\n\n\n\n<p><strong>Transaction Value<\/strong>: Up to <strong>USD\u202f840\u202fmillion<\/strong> (including milestones).<\/p>\n\n\n\n<p><strong>Typical Structure<\/strong> (industry benchmarks):<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront<\/strong>: <strong>USD\u202f200\u2011300\u202fmillion<\/strong> (estimated)<\/li>\n\n\n\n<li><strong>Milestone Payments<\/strong>: <strong>USD\u202f540\u2011640\u202fmillion<\/strong> tied to IND filing, Phase\u202fI\/II\/III completions, regulatory approvals<\/li>\n\n\n\n<li><strong>Royalties<\/strong>: Low\u2011single\u2011digit <strong>sales royalties<\/strong> to Dark Blue\u2019s founders (if applicable)<\/li>\n<\/ul>\n\n\n\n<p><strong>R&amp;D Investment<\/strong>: Amgen plans to invest <strong>USD\u202f150\u2011200\u202fmillion<\/strong> over <strong>3\u20114 years<\/strong> to advance the degrader to <strong>Phase\u202fII proof\u2011of\u2011concept<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the transaction\u2019s closure, integration success, clinical development timelines, and peak sales potential for the MLLT1\/3 degrader. Actual results may differ materially due to clinical trial outcomes, regulatory hurdles, competitive dynamics in AML, and Amgen\u2019s ability to successfully integrate Dark Blue\u2019s technology platform.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Amgen Inc. (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics Ltd., a privately held&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[330,16,4535,912],"class_list":["post-53265","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-amgen","tag-cancer","tag-dark-blue-therapeutics","tag-nasdaq-amgn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Amgen Inc. (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics Ltd., a privately held UK\u2011based biotech advancing first\u2011in\u2011class small\u2011molecule protein degraders for oncology, in a transaction valued at up to USD\u202f840\u202fmillion. The deal adds an investigational dual\u2011target degrader for acute myeloid leukemia (AML) to Amgen\u2019s early\u2011stage oncology pipeline, with promising preclinical data demonstrating anti\u2011cancer activity and potential to overcome treatment resistance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53265\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio\" \/>\n<meta property=\"og:description\" content=\"Amgen Inc. (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics Ltd., a privately held UK\u2011based biotech advancing first\u2011in\u2011class small\u2011molecule protein degraders for oncology, in a transaction valued at up to USD\u202f840\u202fmillion. The deal adds an investigational dual\u2011target degrader for acute myeloid leukemia (AML) to Amgen\u2019s early\u2011stage oncology pipeline, with promising preclinical data demonstrating anti\u2011cancer activity and potential to overcome treatment resistance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53265\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T16:38:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-07T16:38:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53265#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53265\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio\",\"datePublished\":\"2026-01-07T16:38:24+00:00\",\"dateModified\":\"2026-01-07T16:38:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53265\"},\"wordCount\":599,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Amgen\",\"Cancer\",\"Dark Blue Therapeutics\",\"NASDAQ: AMGN\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53265#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53265\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53265\",\"name\":\"Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-07T16:38:24+00:00\",\"dateModified\":\"2026-01-07T16:38:25+00:00\",\"description\":\"Amgen Inc. (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics Ltd., a privately held UK\u2011based biotech advancing first\u2011in\u2011class small\u2011molecule protein degraders for oncology, in a transaction valued at up to USD\u202f840\u202fmillion. The deal adds an investigational dual\u2011target degrader for acute myeloid leukemia (AML) to Amgen\u2019s early\u2011stage oncology pipeline, with promising preclinical data demonstrating anti\u2011cancer activity and potential to overcome treatment resistance.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53265#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53265\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53265#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Amgen Inc. (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics Ltd., a privately held UK\u2011based biotech advancing first\u2011in\u2011class small\u2011molecule protein degraders for oncology, in a transaction valued at up to USD\u202f840\u202fmillion. The deal adds an investigational dual\u2011target degrader for acute myeloid leukemia (AML) to Amgen\u2019s early\u2011stage oncology pipeline, with promising preclinical data demonstrating anti\u2011cancer activity and potential to overcome treatment resistance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53265","og_locale":"en_US","og_type":"article","og_title":"Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio","og_description":"Amgen Inc. (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics Ltd., a privately held UK\u2011based biotech advancing first\u2011in\u2011class small\u2011molecule protein degraders for oncology, in a transaction valued at up to USD\u202f840\u202fmillion. The deal adds an investigational dual\u2011target degrader for acute myeloid leukemia (AML) to Amgen\u2019s early\u2011stage oncology pipeline, with promising preclinical data demonstrating anti\u2011cancer activity and potential to overcome treatment resistance.","og_url":"https:\/\/flcube.com\/?p=53265","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-07T16:38:24+00:00","article_modified_time":"2026-01-07T16:38:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53265#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53265"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio","datePublished":"2026-01-07T16:38:24+00:00","dateModified":"2026-01-07T16:38:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53265"},"wordCount":599,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Amgen","Cancer","Dark Blue Therapeutics","NASDAQ: AMGN"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53265#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53265","url":"https:\/\/flcube.com\/?p=53265","name":"Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-07T16:38:24+00:00","dateModified":"2026-01-07T16:38:25+00:00","description":"Amgen Inc. (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics Ltd., a privately held UK\u2011based biotech advancing first\u2011in\u2011class small\u2011molecule protein degraders for oncology, in a transaction valued at up to USD\u202f840\u202fmillion. The deal adds an investigational dual\u2011target degrader for acute myeloid leukemia (AML) to Amgen\u2019s early\u2011stage oncology pipeline, with promising preclinical data demonstrating anti\u2011cancer activity and potential to overcome treatment resistance.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53265#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53265"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53265#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53265"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53265\/revisions"}],"predecessor-version":[{"id":53269,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53265\/revisions\/53269"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}